Korea's Supreme Court Upholds Lower Courts' Ruling against Pfizer's Lipitor Patent Extension
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Ending nearly two years of court battles over the patent extension of Pfizer's cholesterol drug Lipitor, South Korea's Supreme Court upheld the lower courts' rulings in favor of six local Korean pharmaceutical companies that have been selling generics of Lipitor (atorvastatin)
You may also be interested in...
MNC Products Retain Dominance In Korea As Local Generics Face Challenges
SEOUL - Multinational company products covered by South Korea's national medical insurance system were the most prescribed last year, according to recent government data
MNC Products Retain Dominance In Korea As Local Generics Face Challenges
SEOUL - Multinational company products covered by South Korea's national medical insurance system were the most prescribed last year, according to recent government data
In China, Promotion Trumps Patents
HONG KONG - In the late 1980s, Warner-Lambert researcher Bruce Roth came up with atorvastatin and changed the pharmaceutical market, and social and healthcare awareness factors in the West that made Lipitor the biggest blockbuster ever are starting to show up in China and other Asian countries. Cholesterol, heart attacks and the gamut of cardiovascular diseases are on the rise as diets grow richer, lifestyles more sedentary and smoking remains prevalent